SJF620 is primarily utilized in the field of oncology as a targeted therapeutic agent. It functions by inhibiting specific pathways involved in cancer cell proliferation, making it effective in treating certain types of tumors. Its application is particularly significant in cases where traditional chemotherapy has shown limited efficacy or where precision medicine approaches are required. Additionally, SJF620 is being studied for its potential to enhance the effectiveness of immunotherapy by modulating the tumor microenvironment. Furthermore, SJF620 is under investigation for applications in treating neurological disorders, such as Alzheimer's disease and Parkinson's disease, due to its potential to protect neurons and reduce inflammation in the brain. Preliminary research indicates that SJF620 may offer a novel therapeutic option for conditions lacking effective treatments. Its role in clinical trials continues to expand as researchers explore its broader therapeutic applications and synergistic effects with other treatments.